Osborn Rohs Williams & Donohoe Ltd lowered its position in shares of Novartis AG (NYSE:NVS) by 4.2% during the third quarter, Holdings Channel reports. The firm owned 63,970 shares of the company’s stock after selling 2,824 shares during the period. Osborn Rohs Williams & Donohoe Ltd’s holdings in Novartis AG were worth $5,051,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Capstone Asset Management Co. increased its position in Novartis AG by 0.6% in the third quarter. Capstone Asset Management Co. now owns 115,594 shares of the company’s stock worth $9,127,000 after buying an additional 686 shares during the last quarter. Atria Investments LLC increased its position in Novartis AG by 41.0% in the third quarter. Atria Investments LLC now owns 14,773 shares of the company’s stock worth $1,166,000 after buying an additional 4,298 shares during the last quarter. Weaver C. Barksdale & Associates Inc. increased its position in Novartis AG by 12.6% in the third quarter. Weaver C. Barksdale & Associates Inc. now owns 8,295 shares of the company’s stock worth $655,000 after buying an additional 931 shares during the last quarter. Creative Planning increased its position in Novartis AG by 124.6% in the third quarter. Creative Planning now owns 64,067 shares of the company’s stock worth $5,059,000 after buying an additional 35,547 shares during the last quarter. Finally, Perkins Coie Trust Co increased its position in Novartis AG by 1.7% in the third quarter. Perkins Coie Trust Co now owns 23,052 shares of the company’s stock worth $1,820,000 after buying an additional 381 shares during the last quarter. Hedge funds and other institutional investors own 9.86% of the company’s stock.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Shares of Novartis AG (NYSE:NVS) traded down 0.17% on Tuesday, hitting $68.96. 1,803,283 shares of the company’s stock traded hands. Novartis AG has a 1-year low of $67.28 and a 1-year high of $88.49. The firm’s 50-day moving average price is $72.79 and its 200 day moving average price is $78.41. The company has a market cap of $163.82 billion, a price-to-earnings ratio of 24.32 and a beta of 0.71.

Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, October 25th. The company reported $1.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.19 by $0.04. Novartis AG had a net margin of 13.98% and a return on equity of 15.25%. The company had revenue of $12.13 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the previous year, the company earned $1.27 EPS. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. On average, equities research analysts expect that Novartis AG will post $4.72 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was posted by Daily Political and is the propert of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this article can be viewed at http://www.dailypolitical.com/2016/11/29/novartis-ag-nvs-stake-decreased-by-osborn-rohs-williams-donohoe-ltd.html.

A number of analysts recently weighed in on NVS shares. Argus reaffirmed a “hold” rating on shares of Novartis AG in a report on Thursday, August 25th. Jefferies Group reaffirmed a “buy” rating on shares of Novartis AG in a report on Sunday, October 16th. TheStreet cut shares of Novartis AG from a “buy” rating to a “hold” rating in a report on Wednesday, September 28th. Chardan Capital began coverage on shares of Novartis AG in a report on Tuesday, September 20th. They issued a “buy” rating and a $95.00 price objective on the stock. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Novartis AG in a research note on Friday, November 18th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $88.50.

About Novartis AG

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

5 Day Chart for NYSE:NVS

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.